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Abstract
  
 Heliannuols has a benzoxepine ring that produces anticancer activity by the inhibition 
mechanism of phosphoinositide 3 kinases (PI3K). Heliannuols are a compound that can be 
found in the leaves of sunflower (Helianthus annuus L.). The purpose of this study is to 
predict interactions, toxicity, physicochemical, and pharmacokinetics of Heliannuol A, B, 
C, D, and E based in silico as candidate anticancer drugs. Estrogen receptor beta (ERβ) is 
a new potential therapy for glioma with an antiproliferative effect. Ligands agonist ERβ 
have the potential activity to inhibit the proliferation of glioma cells and the discovery of 
this ligand has opened new therapy through the ERβ to prolong survival in cancer patients. 
Prediction of physicochemical properties based on Lipinski rules and penetrate in the 
blood-brain barrier. Receptor validation shows that 2I0G(A) has a smaller RMSD value than 
2I0G(B), receptor validation is valid if the RMSD value less than 2. The result of molecular 
docking shows that Heliannuols comply with Lipinski rules and have low toxicity. Heliannuols 
also have a similar amino acid with comparison drug (Erteberel), but the rerank score of 
Erteberel still lower than Heliannuols. 
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INTRODUCTION
 Sunflower plant (Helianthus annuus L.) has 
many chemical compounds, especially in the leaves 
of this plant containing monoterpene, diterpene, 
alkaloids, phenols, and lactone sesquiterpenes 
(Ceccarini, 2004). Heliannuols are one of the 
sesquiterpenes which has a benzoxepine ring and 
anticancer activity produced by the inhibition 
mechanism of phosphoinositide 3 kinases (PI3K) 
(Ghantous, et al., 2010; Hefron, et al., 2011; 
Kuntala, et al., 2017; Ren, et al., 2003). Heliannuol 
A, B, C, D, and E were obtained from sunflower 
leaves that had been immersed in water for 24 h and 
extracted with chloroform (CH2Cl2) then observed 
using HPLC with hexane and ethyl acetate solvents 
(Macias, et al., 1994; Macias, et al., 2000; Macias, 
et al., 2002). The new anticancer treatment therapy 
involves estrogen receptor beta-agonists (ERβ) 
by the pathway of inhibiting cancer growth and 
anticancer therapy with estrogen receptors can 
reduce glioma cell proliferation (Sareddy, et al., 
2012; Sareddy and Vadlamudi, 2015). 
 ERβ has quite a different function 
from ERα, ERβ has antiproliferative action and 
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overexpression of ERβ can reduce proliferation in 
cancer cells (Strom, et al., 2004; Hartman, et al., 
2009; Nilsson, et al., 2011). This research focuses 
on estrogen receptor beta agonists because it has the 
potential as an antitumor therapy agent by activating 
beta subtypes and preventing proliferative effects 
on cancer. Ligands that are included as estrogen 
receptor beta-agonists that have the potential activity 
to inhibit the proliferation of glioma cells are DPN 
(Diarylpropionitrile), MFF101, Liquiri-tigenin, and 
LY500307 (comparison drug (Erteberel)) (Sareddy, 
et al., 2012; Sareddy and Vadlamudi, 2015). 
Erteberel is one of the agonists ERβ that has high 
potential in reducing glioma cell proliferation and 
it can penetrate the blood-brain barrier (Sareddy, et 
al., 2016). The discovery of a specific agonists ERβ 
provided naturally has opened the development of 
new therapies through the estrogen receptor beta to 
prolong survival in cancer patients (Sareddy and 
Vadlamudi, 2015). 
 Based on the research by Sareddy, et al. 
(2012) show that ERβ pathway activation is a 
potential therapeutic target for glioma because 
ERβ agonists are under clinical trials and are well 
tolerated with fewer side effects. The use of ERβ 
as a therapeutic agent can be extended to clinical 
use and is predicted to be a new class of drugs 
for treating glioma. Future studies examining the 
mechanism of ERβ in cancer progression will be 
useful for maximizing treatment using ERβ natural 
ligands (Sareddy and Vadlamudi, 2015). The 
purpose of this study was to determine the activity 
of Heliannuols on estrogen receptor beta and the 
lack of information on estrogen receptor beta-
agonists as therapeutic agents in cancer patients, 
encouraging researchers to compile this study.
MATERIALS AND METHODS
Software
 This research uses Chem Bio Draw Ultra 
12.0 application, Avogadro, pkCSM online tool, 
Protox II online tool (accessed on January 2020), 
and Molegro Virtual Docker 6 (Lisensi expires on: 
January 01, 2099).
Target and Template Selection
 The target of this research is the estrogen 
receptor beta 2I0G from Protein Data Bank (https://
www.rcsb.org). The test compounds of this research 
are Heliannuol A, B, C, D, and E where the SMILES 
code from Chem Bio Draw 12.0 and the Erteberel 
SMILES code from PubChem.
Prediction of Physicochemical, 
Pharmacokinetic, and Toxicity Properties
 Prediction of physicochemical properties 
using the pkCSM online tool and the Protox II 
online tool by entering the SMILES code of the 
compound. The prediction of physicochemical 
properties is based on Lipinski’s rules and the 
ability of compounds to penetrate the brain 
barrier membrane. Lipinski’s rules use to evaluate 
compounds that have pharmacological activity with 
predictable physical and chemical properties as 
drug candidates for humans. While the prediction 
of pharmacokinetic properties using the online 
pkCSM tool is based on the absorption, distribution, 
metabolism, and excretion parameters. Toxicity 
prediction using the pkCSM online tool and the 
Protox II online tool based on several parameters 
and toxicity classes according to the Globally 
Harmonized System (GHS).
Molecular Docking 
 Molecular docking using Molegro Virtual 
Docker 6.0 to know the interaction between the 
test compound and the receptor. 2D structures of 
Heliannuol A, B, C, D, and E were drawn using 
Chem Draw Ultra 12.0 and to know the SMILES 
code of the test compounds then 3D structures were 
made using Avogadro and energy minimization 
was performed. Validation of molecular docking 
ERβ (2I0G) using Molegro Virtual Docker 6.0 and 
a docking simulation process was also performed. 
Validation of molecular docking result is the Root 
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Mean Square Deviation (RMSD), the docking 
simulation process can be run if the RMSD value 
was less than 2Å. The parameters used in docking 
simulation include rerank score, bond distance, and 
type of interaction.
RESULTS
Prediction of Physicochemical Properties 
and Toxicity
 Prediction of physicochemical properties 
using Lipinski rules of five with several parameters 
includes molecular weight, the partition coefficient 
of octanol/water (log P), Hydrogen Bond Donors 
(HBD), and Hydrogen Bond Acceptors (HBA). 
Topological  Polar  Surface  Area (TPSA) also a 
parameter to determine compound can penetrate 
the brain barrier membrane (Kelder, et al., 1999). 
The physicochemical test was used to predict that 
the compound has good permeability, high absorp-
tion, and can penetrate the blood-brain barrier. The 
results of physicochemical properties, the ability 
of compounds to penetrate the brain barrier mem-
brane, and toxicity are shown in Table 1.
 The results of physicochemical prediction 
show that all compounds comply with Lipinski 
rules, it can be predicted that all compound easy to 
absorption and has good permeability. The result 
of TPSA showed that all compounds have a TPSA 
value of less than 80, it can be predicted that all 
compounds could penetrate the brain barrier mem-
brane (Hughes, 2008). Heliannuol A, B, and C are 
in toxicity class 4 with Lethal Dose (LD50) 300-2000 
mg/kg. Heliannuol D and Erteberel are in toxicity 
class 5 with LD50 2000-5000 mg/kg. Heliannuol A, 
B, C, D, E, and Erteberel were predicted to be non-
toxic in the AMES Mutagenic test, not toxic in the 
Hepatotoxicity test, and did not cause skin irritation 
in the Skin Sensitization test.
Prediction of Pharmacokinetic Properties
 Prediction of pharmacokinetic properties 
is based on the prediction of absorption, distribu-
tion, metabolism, and excretion (ADME) using the 
Table 1. Prediction of physicochemical and toxicity.
pkCSM online tool. The results of the prediction of 
pharmacokinetic properties are shown in Table 2.
 The result from the prediction of phar-
macokinetic properties shows ADME of the com-
pound, in this research shows that all compound 
is predicted to have good intestinal absorption 
with the value is more than 80% (Chander, et al., 
2017). According to the pkCSM online tool page 
website (http://biosig.uni-melb.edu.au/pkcsm/the-
ory), the compound has a high skin permeability if 
the Log value of Kp>-2.5 cm/h, and all compound 
are predicted have high skin permeability. Caco2 
permeability is good if the Papp value>0.90 cm/s 
and all compounds are predicted to have good per-
meability. Heliannuol C and E do not include as 
Pgp substrates, then they are not predicted to be 
Description: *pkCSM online tool; **Protox II online tool.
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Table 2. Prediction of pharmacokinetic properties.
Description: Vdss (Volume of Distribution at Steady State); BBB (Blood Brain Barrier); CNS (Central Nervous Sys-
tem); CYP2D6 (Cytochrome P2D); CYP3A4 (Cytochrome 3A4); CYP1A2 (Cytochrome 1A2); CYP2C19 (Cyto-
chrome 2C19); CYP2C9 (Cytochrome 2C9); Renal OCT2 (Renal Organic Cation Transporter 2). *The highest 
value of comparative drugs; **The highest value of the first test compound; +The second highest value of 
the test compound; ++Different result from other.
removed from the target cell (Chakraborty and  Ra-
makrishnan, 2016). Heliannuol A, B, C, D, E, and 
Erteberel are not included as Pgp I and II   inhibi-
tors, it predicts that the compound did not inhibit 
the work of the Pgp substrate (Robert and Jarry, 
2003). The distribution volume of the compound 
is declared low if the Log Vdss value <-0.15 and 
high if the Log Vdss value >0.45, all compound 
has good distribution volume. Compounds with 
log BB>0.3 can penetrate the brain barrier mem-
brane while compounds with log BB<-1 cannot  be 
well   distributed in the brain. Compounds with Log 
PS>-2 are considered to be able to penetrate CNS 
while Log PS<-3 are considered  unable to pene-
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Table 3. Validation of molecular docking. 
Receptor 
RMSD (Å) Average±SD (Å) 
Replication I Replication II Replication III  
2I0G (A) 0.4429 0.7535 0.7794 0.6586±0.1872 
2I0G (B) 0.5947 0.8566 0.8296 0.7603±0.1440 
 
 
trate CNS.  All  compound  is predicted to  pene-
trate the brain barrier and central nervous system. 
Heliannuol A, B, C, D, E are predicted not to be 
part of the CYP substrate or inhibitor then the com-
pound is predicted to be metabolized without the 
help of cytochrome enzymes and does not inhibit 
the work of CYP 450. Whereas Erteberel is pre-
dicted to include CYP3A4 substrate and inhibitors 
of CYP1A2, CYP2C19, CYP2C9, CYP2C9, and 
CYP3A4. Heliannuol C is predicted to have a faster 
excretion process than other compounds because 
if the CLTOT value is higher then the excretion is 
faster (Hardjono, et al., 2018). Heliannuol A, B, C, 
D, E, and Erteberel are predicted to not include Or-
ganic Cation Transporter 2 (OCT2)  substrate then 
the compound is predicted to be excreted without 
OCT2 substrate, OCT plays an important role in 
cationic drugs (Koepsell, 2015).
Validation of Molecular Docking System
 RMSD is a parameter for receptor valida-
tion. The validation of molecular docking process 
is carried out by  docking between the native ligand 
and the receptor, if the results obtained are less than 
2, it can be predicted that poses receptor with the 
native ligand is valid (Ruswanto, 2015). Validation 
of molecular docking result are shown in Table 3.
 Validation of molecular docking result in 
table 3 show that the receptor has two ligands and 
the 2I0G(A) ligand has a smaller RMSD value than 
the 2I0G(B) ligand.
Docking Molecular and Interaction of Amino 
Acid
 The docking simulation process uses 
several parameters including the MolDock 
Score, Rerank Score, and H bond. The results of 
 
 
Figure 1. Interaction of amino acids between (a) Heliannuol A, (b) Heliannuol B, (c) Heliannuol C, (d) 
Heliannuol D, (e) Heliannuol E, (f) Erteberel on ERβ with red color as steric bond and blue color as 
hydrogen bond.
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molecular docking are showed by the interaction of 
amino acids and rerank scores are shown in Figure 
1 and Table 4. 
 In Figure 1 and Table 4 are show that 
Heliannuol A has a steric bond with the amino acid 
Leu 339, Heliannuol B has a hydrogen bond Gly 
472, Leu 298, His 475, Heliannuol C has a hydro-
gen bond Lys 401, Val 280, Phe 356, and a steric 
bond Arg 346, Pro 358, Pro 277, His 279, Ala 357, 
Glu 305. Heliannuol D has hydrogen bonds Gly 
472, His 475, Leu 298, Heliannuol E has hydro-
gen bonds Glu 305, Thr 299, and steric bonds Val 
487. Whereas Erteberel has bonds hydrogen His 
475, Gly 472, Leu 339, Arg 346, Glu 305 and steric 
bonds Glu 305.
DISCUSSION
 The purpose of this research was to predict 
interactions, toxicity, and physicochemical proper-
ties of Heliannuol A, B, C, D, and E compounds 
using in silico study as anticancer. Prediction of 
physicochemical properties and toxicity is obtained 
by submitting the compound SMILES code into 
the pkCSM online tool and the ability to  pene-
trate the brain barrier is obtained from the Protox 
II online tool. Heliannuol A, B, C, D, and E can be 
predicted easily absorbed   and  have  good   perme-
ability because  have a molecular weight less than 
500, log P values are less than 5, HBD expressed 
by the number of OH groups and NH is less than 
5, and HBA which is expressed with some O and 
N atoms less than 10 (Lipinski, et al., 2001). All 
compounds have a TPSA value less than 80Å, it 
can be predicted that the compound can penetrate 
the brain barrier membrane (Hughes, 2008). He-
liannuol A, B, and C are in toxicity class 4 which 
means fatal if ingested with LD50 300-2000 mg/kg. 
Heliannuol D and Erteberel are in toxicity class 5 
which  means  it  might  be dangerous if   swallowed 
with LD50 2000-5000 mg/kg (El-Din, et al., 2016). 
All compounds also were predicted to be non-toxic 
Description: *Amino Acid of Heliannuols that same with Erteberel.
Compound 
Hidrogen Bond and 
Distance (Å) 




Heliannuol A - Leu 339 (3.09)* -69.988  
Heliannuol B 
Gly 472 (2.61) 
His 475 (3.32)* 
Leu 298 (2.79) 
- -72.313  
Heliannuol C 
Lys 401 (3.00) 
Val 280 (3.10) 
Phe 356 (2.98) 
Arg 346 (2.70)* 
Pro 358 (2.89) 
Pro 277 (2.79) 
His 279 (2,99) 
Ala 357 (3.15) 
Glu 305 (2,93)* 
-78.532  
Heliannuol D 
Gly 472 (2.60) 
His 475 (3.18)* 
Leu 298 (2.84) 
- -70.814  
Heliannuol E 
Glu 305 (2.60)* 
Thr 299 (3.11) 
Val 487 (3.12) -80.245  
Erteberel 
His 475 (2.69)* 
Gly 472 (3.37) 
Leu 339 (3.10) 
Arg 346 (2.82)* 
Glu 305 (3.29)* 
Glu 305 (2.99)*  -97.857  
Table 4. Interaction of amino acid and rerank score. 
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in the AMES Mutagenic test, not toxic in the liver, 
and did not cause skin irritation. Pharmacokinetic 
properties are  used  to  determine  the  absorp-
tion, distribution, metabolism, and excretion of 
the test compound. The result of pharmacokinetic 
shows that Heliannuols have high absorption and 
can   penetrate the brain barrier membrane where 
these compounds are expected as therapy in glioma 
patients. Besides, Heliannuol C and E are not in-
cluded in the Pgp substrate then these compounds 
are predicted not to be removed from the cell and 
are expected to increase the therapeutic effect of the 
compound. This prediction is expected to be used as 
an additional prediction regarding the effects of the 
compound in the body before proceeding to the in 
vivo and in vitro tests.
 This research shows that the receptor has 
two active sides that bind with the native ligand is 
2I0G(A) and 2I0G(B). Ligand 2I0G(A) has a smaller 
RMSD value than 2I0G(B), it can be predicted that 
the active side of the receptor for the docking simu-
lation is 2I0G(A). The docking process can be per-
formed if the receptor has RMSD value ≤2 and the 
RMSD value from ligand 2I0G(A) is 0.6586Å. Pre-
diction of molecular docking between Heliannuol 
A, B, C, D, and E with estrogen receptors β (ERβ) 
show that Heliannuol E has the lowest energy with 
a rerank score of -69.988 kcal/mol and predicted to 
have the most stable bond among other Heliannuols 
and predicted have the greatest activity. And if the 
result of the rerank score (the value of bond energy) 
is lower (more negative), the  bond between  the 
ligand and receptor is more stable, and the more 
stable bond between the ligand and receptor than 
the activity is high (Hardjono, 2012). 
 The result of amino acid interaction from 
this research includes hydrogen and steric bond. 
Heliannuols have the same several amino acids with 
an amino acid of the Erteberel by hydrogen bonds. 
Hydrogen bonds are non-covalent bonds that play 
a role in the biological activity produced (Much-
taridi, et al., 2018;  Wijaya, et al., 2003). Erteberel 
bind to amino acid His 475, Glu 305, and Arg 346 
with hydrogen bonds, a compound that binds with 
that amino acid can be classified as an ERβ ago-
nist. Estrogen receptor beta agonist bind to amino 
acid Glu 305, Arg 346, His 475 (Meegan and Lloyd, 
2003). Heliannuols have the same amino acid with 
an amino acid of the Erteberel by hydrogen bond, 
but Heliannuol A doesn’t bind to amino acid His 
475, Glu 305, and Arg 346. From the result of this 
study, it can be predicted that Heliannuol B, C, D, E 
have  the  same   function   with   the  Erteberel  as 
an   ERβ  agonist.  Prediction of  physicochemical, 
pharmacokinetic,  and    toxicity  from  Heliannuols 
are predicted to have high absorption, good  per-
meability, can penetrate the blood-brain barrier, and 
toxicity in classes 4 and 5. The  docking  result of 
Heliannuols is not good than the Erteberel because 
Erteberel still has the lowest rerank score than 
Heliannuols.
CONCLUSION
 The conclusion from the research shows 
that Heliannuols have the same amino acid 
with the Erteberel, then can be predicted that 
Heliannuols have the same effect on estrogen 
receptor beta. When looked at its physicochemi-
cal, pharmacokinetics, and toxicity, Heliannuols 
has high absorption, can penetrate the brain barrier 
membrane, has good permeability and toxicity is in 
grades 4 and 5. However, the rerank score of  Erte-
berel is still lower than Heliannuols. And for further 
research, it is recommended that Heliannuols be 
tested on other receptors to produce a lower rerank 
score of test compound than comparison compound.
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